Castagna Maria Grazia, Pilli Tania, Maino Fabio, Marzocchi Carlotta, Cairano Giovanni Di, Cantara Silvia
Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
Arch Endocrinol Metab. 2020 Apr;64(2):185-189. doi: 10.20945/2359-3997000000208. Epub 2020 Mar 27.
The EIF1AX gene mutations have been recently associated with papillary thyroid carcinoma and anaplastic thyroid cancer. According with these reports, the gene as been considered as a drive gene for thyroid cancer development. However, the occurrence of these alterations in benign thyroid lesions is not known and is still under investigation. Some authors have already reported the presence of EIF1AX variants in follicular adenomas and hyperplastic nodules. Here, we describe for the first time a case of a man with the EIF1AX c.338-2A>T splice site mutation in an indeterminate FNA lesion with trabecular adenoma at final histology in the absence of other pathogenetic mutations, demonstrating that further studies are required to better understand EIF1AX role in the tumorigenesis of thyroid carcinoma.
EIF1AX基因突变最近被发现与甲状腺乳头状癌和间变性甲状腺癌有关。根据这些报道,该基因被认为是甲状腺癌发生发展的驱动基因。然而,这些改变在良性甲状腺病变中的发生率尚不清楚,仍在研究中。一些作者已经报道在滤泡性腺瘤和增生性结节中存在EIF1AX变异。在此,我们首次描述了一例男性患者,其在最终组织学检查中为不确定的细针穿刺活检(FNA)病变伴小梁状腺瘤,存在EIF1AX c.338-2A>T剪接位点突变,且不存在其他致病突变,这表明需要进一步研究以更好地了解EIF1AX在甲状腺癌发生中的作用。